Author’s Reply: To the Letter to the Editor by Sorscher

Author: Kimberly H. Allison MD1
View More View Less
Restricted access
  • 1.

    Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:21052122.

    • Search Google Scholar
    • Export Citation
  • 2.

    Gradishar WJ, Anderson BO, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2021. Accessed April 23, 2021. To view the most recent version, visit NCCN.org

    • Search Google Scholar
    • Export Citation
  • 3.

    Press MF, Sauter G, Buyse M, et al. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol 2016;34:35183528.

    • Search Google Scholar
    • Export Citation
  • 4.

    Press MF, Villalobos I, Santiago A, et al. Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice. Arch Pathol Lab Med 2016;140:12501258.

    • Search Google Scholar
    • Export Citation
  • 5.

    Ballard M, Jalikis F, Krings G, et al. ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol 2017;30:227235.

    • Search Google Scholar
    • Export Citation
  • 6.

    Sorscher S. Patients with group2, HER2-negative tumors on ALTERNATIVE. J Clin Oncol 2021;39:1188.

  • 7.

    Johnston SRD, Gradishar WJ. Reply to S. Sorscher. J Clin Oncol 2021;39:11881189.

  • 8.

    Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal woman with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol 2021;39:7989.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 77 77 75
PDF Downloads 21 21 20
EPUB Downloads 0 0 0